Genelux Corporation (GNLX)Healthcare | Biotechnology | Westlake Village, United States | NasdaqCM
2.65 USD
-0.14
(-5.018%) ⇩
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 12:27 a.m. EDT
Despite a high Wall Street price target ($17.50) and positive recent price momentum, GNLX is a deep value trap with negative earnings, massive negative operating margins, and a lack of dividend payments. The recently announced $20M public offering and insider selling signal management financial distress. Technical indicators show the stock is still below its 200-day moving average, operating in a secular downtrend despite a temporary bounce. Avoid until earnings show a path to profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.049186 |
| AutoETS | 0.055065 |
| AutoARIMA | 0.055067 |
| MSTL | 0.057612 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.380 |
| Excess Kurtosis | -0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.596 |
| Market Cap | 118,735,408 |
| Forward P/E | -3.22 |
| Beta | 0.46 |
| Website | https://www.genelux.com |
As of April 19, 2026, 12:27 a.m. EDT: Options activity is extremely thin and heavily skewed. At the near term (May 2026), only ATM calls exist with negligible volume. For July 2026, there is a distinct 'top OI' anchor at the $7.5 strike for both calls and puts, suggesting a speculative range-bound setup or high-implied move expectation far out. Notably, the Ljung-Box p-value (6e-10) indicates severe heteroscedasticity in the price series, meaning recent volatility clusters are not randomly distributed, which dampens directional predictive power for models. The adjusted predicted direction is mildly negative (-5.8%).
| Attribute | Value |
|---|---|
| 52 Week Change | -0.09863943 |
| Address1 | 2,625 Townsgate Road |
| Address2 | Suite 230 |
| All Time High | 40.98 |
| All Time Low | 1.6 |
| Ask | 2.71 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 262,270 |
| Average Daily Volume3 Month | 202,398 |
| Average Volume | 202,398 |
| Average Volume10Days | 262,270 |
| Beta | 0.461 |
| Bid | 2.65 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 0.306 |
| City | Westlake Village |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.65 |
| Current Ratio | 2.431 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.8 |
| Day Low | 2.65 |
| Debt To Equity | 14.596 |
| Display Name | Genelux |
| Earnings Timestamp End | 1,746,562,200 |
| Earnings Timestamp Start | 1,746,562,200 |
| Ebitda | -32,970,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.175 |
| Enterprise To Revenue | 13,084.633 |
| Enterprise Value | 104,677,064 |
| Eps Current Year | -0.82 |
| Eps Forward | -0.8225 |
| Eps Trailing Twelve Months | -0.86 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.6294 |
| Fifty Day Average Change | 0.02060008 |
| Fifty Day Average Change Percent | 0.007834517 |
| Fifty Two Week Change Percent | -9.863943 |
| Fifty Two Week High | 8.535 |
| Fifty Two Week High Change | -5.8849998 |
| Fifty Two Week High Change Percent | -0.68951374 |
| Fifty Two Week Low | 2.255 |
| Fifty Two Week Low Change | 0.39499998 |
| Fifty Two Week Low Change Percent | 0.17516628 |
| Fifty Two Week Range | 2.255 - 8.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,743,400,000 |
| Float Shares | 36,150,702 |
| Forward Eps | -0.8225 |
| Forward P E | -3.2218847 |
| Free Cashflow | -14,364,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 8,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10769 |
| Held Percent Institutions | 0.29719 |
| Implied Shares Outstanding | 44,805,811 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. |
| Long Name | Genelux Corporation |
| Market | us_market |
| Market Cap | 118,735,408 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_11172383 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -32,145,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 118,735,399 |
| Number Of Analyst Opinions | 6 |
| Open | 2.78 |
| Operating Cashflow | -25,268,000 |
| Operating Margins | -1,176.5 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 805 267 9889 |
| Pre Market Change | 0.14999986 |
| Pre Market Change Percent | 5.660372 |
| Pre Market Price | 2.8 |
| Pre Market Time | 1,776,777,034 |
| Previous Close | 2.79 |
| Price Eps Current Year | -3.2317076 |
| Price Hint | 4 |
| Price To Book | 8.660131 |
| Price To Sales Trailing12 Months | 14,841.926 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.345 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -5.01792 |
| Regular Market Day High | 2.8 |
| Regular Market Day Low | 2.65 |
| Regular Market Day Range | 2.65 - 2.8 |
| Regular Market Open | 2.78 |
| Regular Market Previous Close | 2.79 |
| Regular Market Price | 2.65 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 127,488 |
| Return On Assets | -0.77252 |
| Return On Equity | -1.69998 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 44,805,811 |
| Shares Percent Shares Out | 0.07 |
| Shares Short | 3,135,864 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,962,542 |
| Short Name | Genelux Corporation |
| Short Percent Of Float | 0.0712 |
| Short Ratio | 17.03 |
| Source Interval | 15 |
| State | CA |
| Symbol | GNLX |
| Target High Price | 31.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 16.0 |
| Total Cash | 14,595,000 |
| Total Cash Per Share | 0.329 |
| Total Debt | 1,685,000 |
| Total Revenue | 8,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.86 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.84085 |
| Two Hundred Day Average Change | -1.19085 |
| Two Hundred Day Average Change Percent | -0.31004855 |
| Type Disp | Equity |
| Volume | 127,488 |
| Website | https://www.genelux.com |
| Zip | 91,361 |